Related Experiment Video
Updated: Jun 7, 2026
10:52
An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse
Published on: April 7, 2014
[Subconjunctival bevacizumab for corneal neovascularization]
J Gueudry1, F Richez, B Tougeron-Brousseau
1Service d'ophtalmologie, hôpital Charles-Nicolle, 1, rue de Germont, 76031 Rouen cedex, France. julie.gueudry@chu-rouen.fr
Journal Francais D'Ophtalmologie
|November 2, 2010
Summary
Subconjunctival bevacizumab injections effectively reduced corneal neovascularization and improved vision in patients. This treatment was well-tolerated, showing promising results for corneal vascularization management.
Area of Science:
- Ophthalmology
- Vascular Biology
Background:
- Corneal neovascularization (CNV) poses a significant threat to vision.
- Anti-VEGF therapies are increasingly explored for managing CNV.
Purpose of the Study:
- To evaluate the efficacy and safety of subconjunctival bevacizumab injections for treating corneal neovascularization.
- To assess changes in visual acuity and corneal neovascularization extent.
Main Methods:
- A prospective case series involving 12 patients (13 eyes) with corneal neovascularization.
- Subconjunctival injections of bevacizumab (2.5 mg) administered near the limbus.
- Outcomes measured included visual acuity, corneal neovascularization area, and side effects over 120 days.
Main Results:
- A significant reduction in corneal neovascularization area was observed, decreasing from 41.1% to 33.9% by day 120 (p<0.0013).
- Median visual acuity improved from 1.32 to 1.25 LogMAR by day 120.
- The treatment was generally well-tolerated, with no systemic side effects or significant intraocular pressure changes. Three cases of epithelial defects were noted.
Conclusions:
- Subconjunctival bevacizumab is an effective and safe treatment for reducing corneal neovascularization within four months.
- The observed visual acuity improvement suggests potential for enhanced visual outcomes.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...